{"id":475260,"date":"2020-03-20T15:38:01","date_gmt":"2020-03-20T15:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475260"},"modified":"2020-03-20T15:38:01","modified_gmt":"2020-03-20T15:38:01","slug":"herpes-zoster-market-insights-epidemiology-and-market-forecast-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/herpes-zoster-market-insights-epidemiology-and-market-forecast-2030-by-delveinsight_475260.html","title":{"rendered":"Herpes Zoster Market Insights, Epidemiology and Market Forecast 2030 by DelveInsight"},"content":{"rendered":"
\"Herpes<\/a><\/div>\n
DelveInsight’s “Herpes Zoster – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Herpes Zoster, historical and forecasted epidemiology as well as the Herpes Zoster market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

(Albany, US) DelveInsight launched its new report on Herpes Zoster – Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/span><\/p>\n

DelveInsight’s “Herpes Zoster – Market Insights, Epidemiology, and Market Forecast-2030″<\/span> report delivers an in-depth understanding of the Herpes Zoster, historical and forecasted epidemiology as well as the Herpes Zoster market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the report:
<\/strong>1. Around 4% of patients develop a recurrent episode later in life. Recurrent zoster occurs almost exclusively in immunosuppressed people.
2. Around 1 in 3 people in the United States will have shingles at some point in their life.<\/p>\n

Key benefits of the report:<\/strong>
1. Herpes Zoster market report covers a descriptive overview and comprehensive insight of the Shingles epidemiology and Shingles market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span>
2. Herpes Zoster market report provides insights on the current and emerging therapies.<\/span>
3. Shingles market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. Herpes Zoster market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Herpes Zoster market.<\/span><\/p>\n

\"\"<\/span><\/p>\n

Request for free sample pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/herpes-zoster-market<\/p>\n

“Females show a higher proportion of Herpes Zoster prevalence as compared to males in the 7MM.<\/strong>“<\/p>\n

The key players in Herpes Zoster market are:<\/strong>
1. Nobelpharma
2. GC Pharma
3. EyeGene
<\/span><\/p>\n

Drugs covered:<\/strong>
1. NPC-06<\/span>
2. CRV-101<\/span>
3. EG-HZ<\/span><\/p>\n

Table of contents<\/strong>
1. Key Insights<\/span>
2. Executive Summary of Herpes Zoster<\/span>
3. Competitive Intelligence Analysis for Herpes Zoster<\/span>
4. Herpes Zoster Market Overview at a Glance<\/span>
5. Herpes Zoster Disease Background and Overview<\/span>
6. Patient Journey<\/span>
7. Herpes Zoster Epidemiology and Patient Population<\/span>
8. Country Wise Herpes Zoster Epidemiology<\/span>
8.1. United States<\/span>
8.2. EU5 Countries<\/span>
8.3. Assumptions and Rationale<\/span>
8.4. Germany<\/span>
8.5. France<\/span>
8.6. Italy<\/span>
8.7. Spain<\/span>
8.8. United Kingdom<\/span>
8.9. Japan<\/span>
9. Herpes Zoster Treatment<\/span>
10. Herpes Zoster Treatment Algorithm<\/span>
11. Unmet Needs<\/span>
12. Herpes Zoster Marketed Drugs<\/span>
12.1. Shingrix: GlaxoSmithKline<\/span>
12.2. VARIVAX: Merck Sharp & Dohme Corp<\/span>
14. Herpes Zoster Emerging Drugs<\/span>
14.1. Key Cross Competition<\/span>
14.2. NPC-06:Nobelpharma<\/span>
14.3. CRV-101: GC Pharma<\/span>
14.4. EG-HZ: EyeGene<\/span>
15. Herpes Zoster 7 Major Market Analysis<\/span>
15.1. Key Findings<\/span>
15.2. Herpes Zoster market Size in 7MM<\/span>
16. Attribute analysis<\/span>
17. The United States Market Outlook<\/span>
17.1. United States Market Size<\/span>
18. EU-5 Countries: Market Outlook<\/span>
18.1. Germany<\/span>
18.2. France<\/span>
18.3. Italy<\/span>
18.4. Spain<\/span>
18.5. United Kingdom<\/span>
19. Japan: Market Outlook<\/span>
20. Access and reimbursement overview of Herpes Zoster<\/span>
21. KOL Views<\/span>
22. Market Drivers<\/span>
23. Market Barriers<\/span>
24. Appendix<\/span>
25. DelveInsight Capabilities<\/span>
26. Disclaimer<\/span>
27. About DelveInsight<\/span><\/p>\n

Related reports:<\/strong><\/p>\n

Herpes Zoster Pipeline Insight, 2020<\/span><\/span><\/a><\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Yash Bhardwaj
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight’s “Herpes Zoster – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Herpes Zoster, historical and forecasted epidemiology as well as the Herpes Zoster market trends in the United States, EU5 (Germany, Spain, Italy, France, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-475260","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=475260"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475260\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=475260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=475260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=475260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}